BioWorld

June 4, 2008

View Archived Issues

Vertex Sells Royalty Rights to HIV Inhibitors for $160 Million

Vertex Pharmaceuticals Inc. is unloading two HIV protease inhibitors it helped develop in a $160 million deal with GlaxoSmithKline plc in which it agreed to sell rights to future royalties for Lexiva and Agenerase. (BioWorld Today) Read More

New Data Show Avant's Vaccine Doubles Survival in Brain Cancer

Read More

IRX Brings in $25M to Advance Lead Cancer Compound, IRX-2

Read More

NewCo News: NexBio Cuts Off Influenza Virus from its Entry Route

Read More

Gen-Probe Makes Counterbid for Diagnostics Firm Innogenetics

Read More

Other News To Note

Read More

ASCO Roundup: Incyte Slips on Myelofibrosis Data; ImmunoGen Falls, Too

Read More

Clinic Roundup

Read More